


REMARKS

Currently claims 13-24 are pending. Claims 1-12 have been cancelled. Support for the new claims is found in the specification as originally filed. See, for example, pages 27-43 and the Examples therein, and the claims as originally filed. Applicants amend the specification for purposes of adding the priority information, and for correcting obvious errors. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Applicants request that the instant application, as herein amended, be published pursuant to 37 C.F.R. §1.215(c). Applicants have attached herewith a copy of the instant application, as amended, in compliance with the Office electronic filing system requirements.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper and to publish the instant application pursuant to 37 C.F.R. §1.215(c), the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392. If the examiner has any outstanding issues with the pending claims, the examiner is encouraged to telephone the undersigned at (919)483-6334 for expeditious handling.

Respectfully submitted,



Jennifer L. Fox
Attorney for Applicant
Registration No. 52,218

Date: 13 Oct 04
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-6334
Facsimile: 919-483-7988